FATE THERAPEUTICS INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for the quarter ending 2021-09-30 was $13.54M.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for the quarter ending 2020-09-30 was -$7.00K, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for the quarter ending 2020-06-30 was $188.79M.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for the quarter ending 2019-09-30 was $162.43M, a 20.45% increase year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for fiscal 2021 was $432.28M, a 128.98% increase from fiscal 2020.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for fiscal 2020 was $188.78M, a 16.24% increase from fiscal 2019.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for fiscal 2019 was $162.41M, a 20.49% increase from fiscal 2018.
- FATE THERAPEUTICS INC stock issued during period, value, new issues for fiscal 2018 was $134.79M, a 213.62% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-12-31 | $432.28M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $13.54M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $188.78M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$7.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $188.79M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $162.41M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $162.43M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $134.79M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $134.85M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $42.98M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $32.15M 10-K · filed 2018-03-05 | |
| 2013-12-31 | $40.48M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |